Trials / Active Not Recruiting
Active Not RecruitingNCT03424018
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMN 111 | Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. |
Timeline
- Start date
- 2017-12-12
- Primary completion
- 2031-06-01
- Completion
- 2031-06-01
- First posted
- 2018-02-06
- Last updated
- 2026-03-13
Locations
24 sites across 7 countries: United States, Australia, Germany, Japan, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03424018. Inclusion in this directory is not an endorsement.